7 New 4-Star Stocks
Elevance and JD are among the stocks that fell into undervalued territory.

Each week, we screen the US-listed stocks under Morningstar’s coverage for newly undervalued names.
For the week ended Oct. 18, seven stocks dropped into undervalued territory, meaning their Morningstar Ratings changed to 4 or 5 stars. Stocks rated 3 stars are fairly valued according to Morningstar analysts, while those rated 1 or 2 stars are considered overvalued. The seven newly undervalued stocks, ordered by market cap, are:
All data in this article is sourced from Morningstar Direct.
New 4-Star Stocks for the Week Ended Oct. 18
The Morningstar US Market Index rose 0.91% over the past week, leaving the overall US stock market significantly overvalued, hovering at a 10% premium to its fair value estimate on a cap-weighted basis.
Of the 888 US-listed stocks covered by Morningstar analysts:
- 30% are undervalued, 42% are fairly valued, and 28% are overvalued.
- Seven are newly undervalued.
- 20 are newly overvalued.
- Zero moved from a 4-star rating to a 5-star rating.
- Two moved from a 5-star rating to a 4-star rating.
- 10 are no longer undervalued.
Morningstar analysts assign every stock under their coverage a fair value estimate, which is an intrinsic measure of its worth, and an uncertainty rating, which captures the range of potential outcomes for that estimate. A higher uncertainty rating equates to a larger range of prices considered fairly valued. These two metrics and the stock’s current price determine its Morningstar Rating.
Distribution of Star Ratings
Metrics for this Week’s New 4-Star Stocks
Elevance Health
- Morningstar Rating: 4 stars
- One-Week Return: -14.17%
Healthcare plans company Elevance has lost 14.40% over the past three months and 7.07% over the past year. The large-value stock has a narrow economic moat. Elevance is trading at a 22% discount to its fair value estimate of $550, with a medium uncertainty rating.
JD.com
- Morningstar Rating: 4 stars
- One-Week Return: -8.78%
Internet retail company JD has climbed 52.13% over the past three months and 58.98% over the past year. The stock is trading at a 20% discount to its fair value estimate of $50, with a high uncertainty rating. JD is a large-core company with a wide economic moat.
Honda Motor
- Morningstar Rating: 4 stars
- One-Week Return: -2.30%
Auto manufacturer Honda is down 2.79% over the past three months and 4.51% over the past year. The stock’s price is 19% below its fair value estimate of $38, with a high uncertainty rating. The large-value stock has no economic moat.
Li Auto
- Morningstar Rating: 4 stars
- One-Week Return: -6.65%
Auto manufacturer Li has gained 25.62% over the past three months and lost 22.90% over the past year. The large-growth stock has no economic moat. Li is trading at a 23% discount to its fair value estimate of $32.80, with a very high uncertainty rating.
Smurfit WestRock
- Morningstar Rating: 4 stars
- One-Week Return: -2.74%
Packaging and containers company Smurfit WestRock has dropped 4.61% over the past three months and climbed 37.07% over the past year. The stock is trading at a 19% discount to its fair value estimate of $55, with a high uncertainty rating. Smurfit WestRock is a large-value company with no economic moat.
Nio
- Morningstar Rating: 4 stars
- One-Week Return: -16.35%
Auto manufacturer Nio is up 14.98% over the past three months and down 34.01% over the past year. The stock’s price is 31% below its fair value estimate of $7.60, with a very high uncertainty rating. The large-value stock has no economic moat.
Bio-Techne
- Morningstar Rating: 4 stars
- One-Week Return: -2.89%
Biotechnology firm Bio-Techne has lost 6.06% over the past three months and gained 7.93% over the past year. The mid-core stock has a narrow economic moat. Bio-Techne is trading at an 18% discount to its fair value estimate of $87, with a high uncertainty rating.
Correction: A previous version of this story included a table that listed the stocks' one-week returns as one-month returns.
This article was generated with the help of automation and reviewed by Morningstar editors. Learn more about Morningstar’s use of automation.
The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.
